A phase 2 trial of patients receiving hemodialysis via an arteriovenous graft found no benefit from a factor XI inhibitor. The monoclonal antibody MK-2060 does not meaningfully lower arteriovenous ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Factor deficiency or inhibition. The possible causes of the isolated prolonged aPTT in this case include factor deficiencies and factor inhibitors. Prolongation of both the PT and aPTT suggests ...

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...